<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764918</url>
  </required_header>
  <id_info>
    <org_study_id>PR13092</org_study_id>
    <nct_id>NCT02764918</nct_id>
  </id_info>
  <brief_title>Cryptosporidiosis and Enteropathogens in Bangladesh</brief_title>
  <official_title>Field Studies of Cryptosporidiosis and Enteropathogens in Bangladesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the incidence of Cryptosporidiosis in Bangladeshi
      children and describe the acquired immune response to the pathogen as well investigate the
      potential of human genetic susceptibility.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Cryptosporidiosis</measure>
    <time_frame>Birth to 4 years old</time_frame>
    <description>To be completed on children</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal Myeloperoxidase (MPO)</measure>
    <time_frame>Once, during the 3rd trimester of pregnancy</time_frame>
    <description>To be conducted on mothers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Regenerating Islet-Derived 1 Beta (Reg 1B)</measure>
    <time_frame>Once, during the 3rd trimester of pregnancy</time_frame>
    <description>To be conducted on mothers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal biophysical profile via ultrasound</measure>
    <time_frame>Once, at the start of the 3rd trimester of pregnancy</time_frame>
    <description>To be conducted on mothers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast milk immunoglobulin A (IgA)</measure>
    <time_frame>From child's birth to 4 months postpartum</time_frame>
    <description>To be conducted on mothers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socioeconomic status questionnaire</measure>
    <time_frame>At enrollment</time_frame>
    <description>To be conducted on mothers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Household sanitation questionnaire</measure>
    <time_frame>At enrollment</time_frame>
    <description>To be conducted on mothers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Myeloperoxidase (MPO)</measure>
    <time_frame>Birth to 4 years old</time_frame>
    <description>To be conducted on children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Regenerating Islet-Derived 1 Beta (Reg 1B)</measure>
    <time_frame>Birth to 4 years old</time_frame>
    <description>To be conducted on children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum soluble cluster of differentiation 14 (sCD14)</measure>
    <time_frame>Birth to 4 years old</time_frame>
    <description>To be conducted on children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum interleukin 14 (IL 14)</measure>
    <time_frame>Birth to 4 years old</time_frame>
    <description>To be conducted on children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum interleukin 1B (IL 1B)</measure>
    <time_frame>Birth to 4 years old</time_frame>
    <description>To be conducted on children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of 1300 known single nucleotide polymorphisms</measure>
    <time_frame>once: at 4 years old</time_frame>
    <description>To be conducted on children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polymerase chain reaction (PCR) for common diarrheal pathogens</measure>
    <time_frame>Birth to 4 years old</time_frame>
    <description>To be conducted on children's diarrheal stool</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cryptosporidiosis</condition>
  <arm_group>
    <arm_group_label>Children</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Mothers</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Mother-child pairs from the Mirpur Neighborhood of Dhaka, Bangladesh
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mother willing to sign informed consent form.

          -  Healthy infant

          -  No obvious congenital abnormalities or birth defects.

          -  Stable household with no plans to leave the area for the next one year.

        Exclusion Criteria:

          -  Parents are not willing to have child's blood drawn.

          -  Parents are planning to enroll child into another interventional clinical study during
             the time period of this trial that could affect the outcomes of this study.

          -  Mother not willing to have blood drawn and breast milk extracted.

          -  Parents not willing to have field research assistant in home two times per week.

          -  History of seizures or other apparent neurologic disorders.

          -  Infant has any sibling currently or previously enrolled in this study, including a
             twin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The International Centre for Diarrhoeal Disease Research, Bangladesh</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>William Petri, MD</investigator_full_name>
    <investigator_title>Division Chief, Infectious Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryptosporidiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

